213 related articles for article (PubMed ID: 8572651)
1. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
6. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
8. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
[TBL] [Abstract][Full Text] [Related]
11. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
12. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
[TBL] [Abstract][Full Text] [Related]
13. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
[TBL] [Abstract][Full Text] [Related]
14. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
16. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
